- Stocks
- Healthcare
- NASDAQ: AMGN

Price (delayed)

$233.02

Market cap

$124.65B

P/E Ratio

19.7

Dividend/share

$7.58

EPS

$11.83

Enterprise value

$155.97B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

The P/E is 26% below the 5-year quarterly average of 26.6 and 10% below the last 4 quarters average of 22.0

AMGN's EPS is up by 19% year-on-year and by 16% since the previous quarter

Amgen's equity has soared by 164% from the previous quarter but it has plunged by 71% YoY

The debt rose by 11% year-on-year

What are the main financial stats of AMGN

Market
Valuations
Earnings

Shares outstanding

534.93M

Market cap

$124.65B

Enterprise value

$155.97B

Price to earnings (P/E)

19.7

Price to book (P/B)

51.46

Price to sales (P/S)

4.73

EV/EBIT

17.83

EV/EBITDA

12.87

EV/Sales

5.91

Revenue

$26.38B

EBIT

$8.75B

EBITDA

$12.12B

Free cash flow

$8.36B

Per share
Balance sheet
Liquidity

EPS

$11.83

Free cash flow per share

$15.62

Book value per share

$4.53

Revenue per share

$49.32

TBVPS

$57.01

Total assets

$59.29B

Total liabilities

$56.88B

Debt

$36.52B

Equity

$2.42B

Working capital

$6.7B

Debt to equity

15.1

Current ratio

1.53

Quick ratio

0.99

Net debt/EBITDA

2.58

Margins
Efficiency
Dividend

EBITDA margin

45.9%

Gross margin

75.8%

Net margin

24.9%

Operating margin

35.5%

Return on assets

10.8%

Return on equity

144.1%

Return on invested capital

18.7%

Return on capital employed

18.7%

Return on sales

33.1%

Dividend yield

3.25%

DPS

$7.58

Payout ratio

64.1%

How has the Amgen stock price performed over time

Intraday

1.12%

1 week

3.11%

1 month

-3.86%

1 year

10.21%

YTD

3.58%

QTD

3.38%

How have Amgen's revenue and profit performed over time

Revenue

$26.38B

Gross profit

$19.99B

Operating income

$9.36B

Net income

$6.58B

Gross margin

75.8%

Net margin

24.9%

AMGN's operating income is up by 26% year-on-year and by 17% since the previous quarter

The company's operating margin rose by 22% YoY and by 17% QoQ

The net income has grown by 15% from the previous quarter and by 14% YoY

The net margin rose by 15% since the previous quarter and by 11% year-on-year

What is Amgen's growth rate over time

What is Amgen stock price valuation

P/E

19.7

P/B

51.46

P/S

4.73

EV/EBIT

17.83

EV/EBITDA

12.87

EV/Sales

5.91

The P/E is 26% below the 5-year quarterly average of 26.6 and 10% below the last 4 quarters average of 22.0

AMGN's EPS is up by 19% year-on-year and by 16% since the previous quarter

Amgen's equity has soared by 164% from the previous quarter but it has plunged by 71% YoY

The stock's price to book (P/B) is 140% more than its 5-year quarterly average of 21.4 but 12% less than its last 4 quarters average of 58.6

The P/S is 11% less than the 5-year quarterly average of 5.3 and 3.5% less than the last 4 quarters average of 4.9

The revenue has grown by 3.5% year-on-year

How efficient is Amgen business performance

The ROE has soared by 138% YoY and by 52% from the previous quarter

AMGN's return on assets is up by 17% year-on-year and by 16% since the previous quarter

AMGN's return on sales is up by 13% since the previous quarter and by 10% year-on-year

The ROIC has grown by 11% YoY and by 9% from the previous quarter

What is AMGN's dividend history

DPS

$7.58

Dividend yield

3.25%

Payout ratio

64.1%

Recent dividends

How did Amgen financials performed over time

Amgen's total assets is 4.3% more than its total liabilities

Amgen's current ratio has increased by 17% YoY and by 6% from the previous quarter

AMGN's quick ratio is up by 15% year-on-year and by 10% since the previous quarter

Amgen's equity has soared by 164% from the previous quarter but it has plunged by 71% YoY

AMGN's debt to equity has shrunk by 62% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.